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Previous Mendelian randomization (MR) studies on 25-hydroxyvitamin D (25(OH)D) and
cancer have typically adopted a handful of variants and found no relationship between 25(OH)D
and cancer; however, issues of horizontal pleiotropy cannot be reliably addressed. Using a larger
set of variants associated with 25(OH)D (74 SNPs, up from 6 previously), we perform a unified
MR analysis to re-evaluate the relationship between 25(OH)D and ten cancers. Our findings are
broadly consistent with previous MR studies indicating no relationship, apart from ovarian
cancers (OR 0.89; 95% C.I: 0.82 to 0.96 per 1 SD change in 25(OH)D concentration) and basal
cell carcinoma (OR 1.16; 95% C.I.: 1.04 to 1.28). However, after adjustment for pigmentation
related variables in a multivariable MR framework, the BCC findings were attenuated. Here we
report that lower 25(OH)D is unlikely to be a causal risk factor for most cancers, with our study
providing more precise confidence intervals than previously possible.
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V itamin D is an essential fat-soluble vitamin primarilycreated when the skin is exposed to ultraviolet radiation.In addition to maintaining musculoskeletal health, animal
models and in-vitro studies suggest vitamin D has anti-cancer
properties, as vitamin D receptors can regulate growth and
apoptosis of tumour cells1,2. Vitamin D, whether produced in the
skin or consumed, undergoes 2 hydroxylation steps to produce
the active form. The first of these produces 25-hydroxyvitamin D
(25(OH)D) which can be measured to determine vitamin D
status. Given that serum 25(OH)D levels in the body can be
readily modified through supplementation, there has been great
interest in evaluating the role of vitamin D in cancer
prevention3,4.
The relationship between vitamin D and cancer continues to be
debated5–9. Controlling for confounding in observational studies
is challenging, so several studies have used Mendelian randomi-
zation (MR) to investigate whether genetic evidence support a
causal role for 25(OH)D levels on cancers. Since genetic variants
are randomised at meiosis, MR-based inference of the relation-
ship between 25(OH)D and cancers via genetic proxies is less
likely to be affected by reverse causality and confounding. Initial
MR studies have offered some insights into a potentially causal
relationship, although all used only a handful of SNPs and since
some different studies have reached contradictory
conclusions10,11, there is a need for greater clarity on the issue.
For most cancers, findings from MR support a null relationship
between 25(OH)D and cancer risk12, but the confidence intervals
remain wide for many cancers and it is not possible to exclude
clinically relevant causal effects. All previous studies relied on at
most 6 SNPs associated with 25(OH)D; these cumulatively
explain ~2% of variation in 25(OH)D13–17. While the biological
pathways linking these variants to serum 25(OH)D are generally
well understood, if more instruments were available, these would
explain a larger portion of the phenotypic variance in 25(OH)D,
while recently developed multi-instrument based MR sensitivity
analyses (such as MR-Egger or median-based approaches) would
provide additional assurance that the MR assumptions are not
violated18. In particular, it is difficult to assess the potential for
bias due to residual pleiotropy with a small number (i.e. <10) of
variants. Moreover, the magnitude and scale of the SNP-25(OH)
D associations differ among MR studies for 25(OH)D and cancer
depending on the population studied in the genome-wide asso-
ciation study (GWAS) datasets used to probe these genetic
association (i.e. differences in the relationship between genetically
predicted 25(OH)D and cancer risk might be induced by varia-
tion in the SNP-25(OH)D effect sizes across sub-European
ancestries). These limitations complicate the interpretation of MR
findings on 25(OH)D and cancer risk published to date.
The recent release of individual-level data on serum 25(OH)
D concentration for more than 400,000 people in the UK
Biobank (UKB) provided an avenue for these issues to be
revisited (http://www.ukbiobank.ac.uk/wp-content/uploads/
2013/11/ukb_biomarker_panel_website_revised_June15.pdf).
The GWAS on 25(OH)D in the UK Biobank is approximately
four times larger than any previous study and would be
expected to dramatically increase the number of candidate 25
(OH)D instruments for the multi-SNP approach (see also the
very recently published 25(OH)D GWASs19,20), leading to a
well-powered MR analysis while enabling a wider arsenal of MR
techniques21–25 to address issues of horizontal pleiotropy,
assess mediating pathways, and control for genetic hetero-
geneity among instruments.
In this work, we present findings from the MR analysis for the
association between 25(OH)D and the risk of several common
cancers using >60 25(OH)D-associated SNPs. We also report
findings from Multivariable MR25 approaches that were used to
account for related exposures, e.g. skin tanning and pigmentation
that may act through sun exposure on skin cancers. We finally
compare our revised findings with those reported from earlier
MR studies.
Results
In the UKB 25(OH)D GWAS, we identified 74 independent genetic
instruments for 25(OH)D which together explained close to 4.0% of
the phenotypic variation in serum 25(OH)D. All of the 25(OH)D
variants used in previous MR analyses were successfully replicated,
with comparable SNP-25(OH)D effect sizes (see Supplementary
Table 1). We also identified one 25(OH)D variant located near the
HAL gene, which was previously reported to influence the risk of
skin cancers26. We removed this variant from our MR analyses on
skin cancers, although the variant only explained 0.05% of 25(OH)
D variation. Based on the estimated proportion of 25(OH)D var-
iance explained by SNP of 4.0%, the power to detect moderate effect
sizes (OR of 1.2 or more per 1 standard deviation (SD) increase in
25(OH)D level) is adequate for most cancers (Supplementary
Table 2). In the UKB, a 1SD increase in 25(OH)D levels roughly
translates to a 20-nmol/L increase in serum 25(OH)D level, which is
the upper bound for the amount of 25(OH)D attainable through
vitamin D supplementation (i.e. an increase of ~1000 IU/day)27.
Sample sizes for each of the cancers evaluated are shown in Table 1.
The estimated OR per 1 SD increase in genetically predicted 25
(OH)D on cancer risks using the traditional 25(OH)D SNP
instruments (n= 6) and the larger set of SNP instruments identified
from the UK Biobank (n= 79) are shown separately in Table 2.
Consistent with the MR findings based on traditional genetic
instruments, we found no evidence for a causal association between
25(OH)D and the risk of breast, prostate, lung, melanoma and
Barret’s oesophagus/oesophageal adenocarcinoma combined
(BEEA). However, higher 25(OH)D concentration was associated
with reduced risk of epithelial ovarian cancer (EOC) (OR 0.89 [95%
CI 0.82–0.96]), with a point estimate similar to those obtained from
previous studies but with a narrower confidence interval. Subtype
analyses for cancers with available data did not detect strong het-
erogeneity of effect sizes between subtypes. Evaluation of MR
associations under various other MR models (MR-Egger, MR
PRESSO, MR mode- and median-based models; see Supplementary
methods) showed consistency with the original inverse-variance
weighted (IVW) estimates, providing evidence against bias due to
horizontal and/or directional pleiotropy (Fig. 1). The comparison of
our MR findings with those obtained from previous work is shown
in Table 3.
It can be challenging to interpret the univariable MR association
between 25(OH)D and skin cancers (i.e. melanoma and keratino-
cyte cancers (KC)) given the potential confounding pathways
through pigmentation and skin aging which are established risk
factors for these cancers28. The univariable MR associations suggest
higher 25(OH)D levels increase risk of basal cell carcinoma (BCC)
(OR= 1.16 [1.04–1.28], while the OR for melanoma was smaller
with confidence intervals overlapping 1 (OR 1.05 [0.90–1.23]).
Effect sizes were widely consistent when we adjusted our MR model
through a multivariable MR framework accounting for the pathway
linking the 25(OH)D SNPs with childhood sunburn episodes and
skin colour (Table 4). The effect estimates for melanoma (OR 1.16
[0.94–1.43]) and SCC (OR 1.08 [0.89–1.31]) in the multivariable
model increased very slightly, though the confidence interval
overlapped the null. For SCC, the multivariable adjusted estimate
for vitamin D showed minor attenuation towards the null (OR 1.15
[0.99–1.32]). We note that the strength of the adjustment is hin-
dered by the lack of accuracy in self-reported data and we also
omitted the time spent outdoors phenotypes due to lack of power.
MR estimates obtained using the conventional approach of
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excluding variants showing evidence of pleiotropic association with
these risk factors were similar showing no clear relationship
between vitamin D and skin cancer but with wider confidence
intervals (Supplementary Table 3).
We then examined whether the MR approach suggested a link
from cancer risk to altered 25(OH)D (which could hypothetically
happen in observational studies if a person had lower vitamin D
levels due to chronic ill health as a consequence of reduced sun
exposure). For most cancers, we found little evidence for an effect
of higher genetic liability to cancers altering serum 25(OH)D levels,
apart from for SCC although the resultant effect estimate was
negligibly small (beta= 0.01, se= 0.004; SD change in 25(OH)D
per doubling of odds of SCC) as shown in Supplementary Table 4.
Results for individual subtypes in the reverse MR analyses are not
reported, as the statistical power was too low to detect meaningful
associations.
Sensitivity analyses. Whilst the implementation of more SNP
instruments would usually translate to better trait prediction, and
hence better power for MR, it also has the potential to introduce
higher levels of heterogeneity amongst the effects of the genetic
instruments. Using the computed cochran Q statistics for each trait-
pair evaluated in the main analyses, 7 out of 19 associations reveal
moderate evidence of heterogeneity among effect sizes estimated by
the 25(OH)D instruments. However, the IVW point estimates for
these heterogenous trait associations were not meaningfully differ-
ent from those estimated via pleiotropy-robust techniques (such as
MR-PRESSO). To validate the 25(OH)D and melanoma findings,
the estimated OR for melanoma after removing potentially
pleiotropic variants that are associated with sunburn and
pigmentation-related traits was 1.02 (0.90–1.16) which is not
meaningfully different from the original findings (1.09 [0.97–1.23];
Supplementary Table 3). Using sex-specific instruments did not
change the null 25(OH)D inference for breast, prostate, endo-
metrial, and the inverse association with ovarian cancer (Supple-
mentary Table 5). We finally evaluated our MR associations using
the recently published Revez et al.19 25(OH)D genetic instruments
that accounts for vitamin D supplementation use - our findings
were essentially unchanged (Supplementary Table 6).
Discussion
Overall, our large multi-instrument approach strengthens con-
fidence in previously established null findings for most cancers,
except for ovarian cancer10. With more than seventy independent
25(OH)D instruments validated in the UKB GWAS explaining ~4%
of variation in 25(OH)D, our revised MR estimates have greater
robustness compared to previous MR findings between 25(OH)D
and individual cancers by enabling estimation of the MR associa-
tion using various MR methods and sensitivity analyses, aiding the
triangulation of (or the lack of) causality. Our MR finding on
endometrial cancer showed little or no effect of lower 25(OH)D
influecing endometrial cancer risk. For BCC there was an initial
positive association, although this was attenuated in multivariable
and sensitivity analyses Fig. 1.
For breast and prostate cancer, our estimates were similar to
those presented in Jiang and colleagues29, supported with similar
estimates obtained from the other MR sensitivity models (Table 3).
Our power to evaluate the MR association between pancreatic, lung
cancer and neuroblastoma remained relatively poor due to the
limited number of cases present in the MR-base repository. Some
previous studies considered 25(OH)D on the untransformed scale
and some used the log scale. Supplementary Table 7 provides a
comparison of our estimates on the two scales; broadly speaking the
results are qualitatively similar.
For ovarian cancer, Yarmolinsky et al.10 previously reported a
non-significant result but when we add additional SNP instruments,




Number of cases Source (PMID) Studies
Barrett’s oesophagus (BE) and
oesophageal cancer
17,159 10,279 27527254 BEACON+ BONN+OXFORD (BE only)+
CAMBRIDGE
Barrett’s oesophagus (BE) 17,159 6167 27527254
Oesophageal cancer 17,159 4112 27527254
Breast cancer 105,974 122,977 29059683 BCAC
ER+ breast cancer 105,974 69,501 29059683
ER- breast cancer 105,974 21,468 29059683
Endometrial cancer 108,979 12,906 30093612 ECAC
EC endometrial cancer 46,126 8758 30093612
NEEC endometrial cancer 35,447 1230 30093612
Lung cancer 15,861 11,348 24880342 ILCCO (MR-Base)
Lung adenocarcinoma 14,894 3442 24880342
Squamous cell lung cancer 15,038 3275 24880342
Melanoma skin cancer 26,409 15,990 26237428 GenoMEL
Keratinocyte cancers QSKIN, 23andMe
Squamous cell carcinoma 285,355 7400 31174203
Basal cell carcinoma 279,049 14,940 31174203
Neuroblastoma 3254 1627 23222812 MR-Base
Ovarian cancer 40,941 25,509 28346442 OCAC
Clear cell 40,941 1366 28346442
Endometrioid 40,941 2810 28346442
High-grade serous 40,941 13,037 28346442
Low-grade serous 40,941 1012 28346442
Mucinous 40,941 1417 28346442
Pancreatic cancer 1939 1896 19648918 PanScan (MR-Base)
Prostate cancer 61,106 79,148 29892016 PRACTICAL
ER refers to oestrogen receptor status. EC and NEEC endometrial cancer refer to the endometrioid and non-endometrioid endometrial cancer subtypes. BE refers to Barrett's oesophagus.
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we find a significant association. To aid understanding of the dif-
ference between the results we used the UKB-derived estimates for
the six initially identified SNP instruments. For these SNPs we
obtained an estimate which is quite different to that in Yarmolinsky
et al.10. Most of the discrepancy appears to be the result of Yar-
molinsky and colleagues10 mis-coding two of the 25(OH)D-
increasing alleles at rs3755967 and rs8018720 (Supplementary
Table 8). Note that Yarmolinsky et al.10 report results on the log 25
(OH)D scale, although this does not markedly influence results and
most of the discrepancy is due to the allele coding issue. When we
expanded the set of SNPs from 6 to 74, the point estimate remained
consistent and the confidence intervals narrowed (OR changes from
0.92 [95% CI 0.83–1.02] to 0.89 [0.82–0.96]).
The study by Winsløw et al.28 using data from the Danish
cohorts of 103 084 participants reported no evidence for an
association between 25(OH)D and KC, with OR of 1.11 (95%
CI 0.91–1.35) for a 20-nmol/L increase in 25(OH)D. In our
univariable MR findings, we found initial evidence for an
association with BCC (OR 1.18 [95% CI 1.05–1.33]) but not
SCC (OR 1.02 [95% CI 0.88–1.19]). When we adjust for the
potential confounding pathways through traits related to sun
exposure, the MR association between 25(OH)D and BCC
attenuated and the confidence intervals overlapped the null.
While our MR findings remain consistent with a potentially
small adverse effect, there is insufficient evidence to establish
vitamin D as a causal risk factor for BCC. The findings from our
univariable and multivariable MR analysis on melanoma indi-
cate no strong link between 25(OH)D and risk of melanoma,
yielding similar conclusions to previous work30.
Our present MR results on 25(OH)D and endometrial cancer
was based data from the the largest endometrial cancer consortium
(ECAC). Findings from a previous meta-analysis of prospective
observational studies did not show strong evidence of an association
between 25(OH)D and endometrial cancer risk (summary relative
risk 0.85 [95% CI 0.47–1.53] for high vs low 25(OH)D levels)31.
Two previous trials of vitamin D3 (cholecalciferol) or calcitriol
supplementation found no strong association with endometrial
cancer32,33, considered in a Cochrane review34, but were not
powered to detect significant associations for cancer endpoints. The
suggestive (inverse) results of the trial32 most regularly cited by
vitamin D proponents has been questioned in the literature due to
several possible shortcomings in design, analysis and/or report-
ing35–37. Our MR estimate confirms findings from observational
studies and randomised clinical trials (RCTs), showing little support
that 25(OH)D is an important risk factor for endometrial cancer,
with sufficient power to rule out moderate (i.e. OR > 1.2) effect
sizes. Furthermore, our subtype analyses show limited evidence that
the MR association differed between endometrioid and non-
endometrioid endometrial cancer.
Our study approach has several advantages. Firstly, our discovery
sample used to identify 25(OH)D instruments was very large, with a
sample size close to five times larger than those obtained from
previous 25(OH)D GWAS. Furthermore, the homogeneity in
measurement and bio-assay resulted in a higher quality 25(OH)D
phenotype as every recruitment centre in the UKB adopted the
same serum extraction protocol. The UKB instruments combined
explained 4.0% of the phenotypic variance, almost doubling the
variance explained by 25(OH)D SNPs compared to those used in
Table 2 Revised estimate for the association between one SD increase in genetically predicted serum 25(OH)D and cancer risk
using UK Biobank 25(OH)D instruments.
Cancers Revised heterogeneity-adjusted estimate
using all UKB 25(OH)D instruments
Revised heterogeneity-adjusted estimate using all UKB 25(OH)D
instruments
SNPs OR (95% CI) P-value SNPs OR (95% CI) P-value Detected outliers via
MR-PRESSO
BEEA 6 1.04 (0.88–1.23) 0.65 76 0.98 (0.85–1.14) 0.98 0
BE 6 1.12 (0.86–1.44) 0.4 76 1.00 (0.84–1.18) 0.97 0
EA 6 0.90 (0.72–1.13) 0.36 76 0.97 (0.78–1.20) 0.76 0
Breast cancer 6 1.01 (0.96–1.06) 0.68 74 1.03 (0.97–1.09) 0.38 5
ER+ breast cancer 6 1.00 (0.95–1.07) 0.88 74 1.04 (0.97–1.12) 0.3 5
ER- breast cancer 6 1.00 (0.91–1.09) 0.94 74 1.01 (0.92–1.12) 0.38 5
Endometrial cancer 5 0.92 (0.81–1.05) 0.24 75 0.95 (0.83–1.09) 0.46 2
EC 5 0.93 (0.79–1.08) 0.33 75 0.93 (0.81–1.08) 0.36 1
NEEC 5 0.89 (0.61–1.31) 0.55 75 1.02 (0.76–1.36) 0.91 0
Lung Cancer 5 1.16 (0.88–1.54) 0.29 65 0.94 (0.78–1.13) 0.5 0
LAC 5 1.17 (0.80–1.72) 0.41 65 0.91 (0.67–1.18) 0.462 0
SCLC 5 1.03 (0.83–1.29) 0.77 65 0.97 (0.76–1.26) 0.843 0
Melanoma 5 1.04 (0.89–1.20) 0.64 69 1.05 (0.90–1.23) 0.55 1
NMSC SCC^ 6 0.96 (0.80–1.15) 0.64 77 1.02 (0.88–1.19) 0.77 0
NMSC BCC^ 6 1.08 (0.92–1.28) 0.35 77 1.16 (1.04–1.28) 0.01 1
Neuroblastoma 2 0.62 (0.27–1.41) 0.25 26 0.74 (0.42–1.29) 0.29 0
Epithelial ovarian cancer 6 0.92 (0.83–1.02) 0.12 76 0.89 (0.82–0.96) 0.02 0
Clear Cell 6 0.87 (0.63–1.20) 0.39 76 0.87 (0.64–1.18) 0.36 0
Endometrioid 6 1.00 (0.80–1.27) 0.97 76 0.94 (0.77–1.15) 0.55 0
High-Grade serous 6 0.91 (0.81–1.04) 0.16 76 0.92 (0.82–1.03) 0.15 0
Low-Grade serous 6 1.05 (0.71–1.54) 0.82 76 0.99 (0.71–1.37) 0.94 0
Mucinous 6 0.94 (0.74–1.20) 0.62 76 0.94 (0.74–1.18) 0.59 0
Pancreatic cancer 2 1.10 (0.52–2.33) 0.81 27 0.95 (0.54–1.69) 0.87 0
Prostate cancer 5 1.02 (0.93–1.14) 0.65 75 1.11 (0.93–1.33) 0.25 1
ER refers to oestrogen receptor status. EC and NEEC endometrial cancer refer to the endometrioid and non-endometrioid endometrial cancer subtypes. Revised estimates derived using the MR-PRESSO
model which corrects for heterogeneity among SNP-effect sizes and outliers. Revised OR estimates reflect a 1 SD change in genetically predicted serum 25(OH)D concentration, which roughly translates
to a 20-nmol/L change in 25(OH)D in the UK Biobank. All P-values derived from z-scores are two-sided and unadjusted for multiple comparison unless otherwise stated.
BE Barrett’s oesophagus. EA oesophageal adenocarcinoma. SCC squamous cell carcinoma. BCC basal cell carcinoma. LAC lung adenomacarcinoma. SCLC squamous cell lung cancer. NMSC non-melanoma
skin cancer. SCC squamous cell carcinoma. BCC basal cell carcinoma.
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previous studies (2.4%). These 25(OH)D instruments were also
found to be associated with 25(OH)D in a recently published formal
25(OH)D GWAS analysis by Manousaki et al.20 using the same
UKB data. For the previously known SNPs from the SUNLIGHT
GWAS14 our SNP instruments (in UKB) showed comparable 25
(OH)D effect sizes. Our unified framework allows for direct com-
parison of MR findings for various cancers, as the same set of SNP-
25(OH)D effect sizes were used across all cancers. Finally, unlike the
Fig. 1 MR association between 1SD increase in genetically predicted 25(OH)D concentration and risk of cancers estimated via multiple two-sample
MR model. BE and EA combined refers to Barrett’s oesophagus and oesophageal cancer combined. The y-axis represents the estimated OR (and the
corresponding 95% CI) on individual cancers per 1 SD change in genetically predicted 25(OH)D.
Table 3 Comparison of revised MR estimates on 25(OH)D and cancer risk against previous findings.
Previous IVW MR findings IVW MR estimates based on UKB 25(OH)D instruments
Cancers OR (95% CI) Unit P-value OR (95% CI) Unit P-value Scaling from per SD
increase)
BEEA63 – – – 0.98 (0.85–1.14) 20 nmol/L 0.82 Multiply by 1
BE 1.21 (0.7–1.92) 20 nmol/L 0.41 1.00 (0.84–1.18) 20 nmol/L 0.97 Multiply by 1
EA 0.68 (0.39–1.92) 20 nmol/L 0.18 0.97 (0.78–1.20) 20 nmol/L 0.76 Multiply by 1
Breast cancer29 1.02 (0.97–1.08) 25 nmol/L 0.47 1.03 (0.93–1.13) 25 nmol/L 0.60 Multiply by 1.25
ER+ breast cancer 1.00 (0.94–1.07) 25 nmol/L 0.99 1.04 (0.93–1.16) 25 nmol/L 0.51 Multiply by 1.25
ER- breast cancer 1.02 (0.90–1.16) 25 nmol/L 0.75 1.00 (0.88–1.15) 25 nmol/L 0.94 Multiply by 1.25
Endometrial cancer – – – 0.93 (0.80–1.07) 20 nmol/L 0.32 Multiply by 1
EC – – – 0.92 (0.79–1.08) 20 nmol/L 0.32 Multiply by 1
NEEC – – – 1.01 (0.73–1.41) 20 nmol/L 0.94 Multiply by 1
Lung Cancer53 0.98 (0.70–1.38) 25 nmol/L 0.93 0.94 (0.78–1.13) 25 nmol/L 0.50 Multiply by 1.25
LAC 0.93 (0.55–1.58) 25 nmol/L 0.81 0.91 (0.67–1.18) 25 nmol/L 0.46 Multiply by 1.25
SCLC 1.02 (0.60–1.73) 25 nmol/L 0.95 0.97 (0.76–1.26) 25 nmol/L 0.84 Multiply by 1.25
Melanoma30 1.06 (0.95–1.19) 20 nmol/L 0.3 1.09 (0.92–1.28) 20 nmol/L 0.31 Multiply by 1
NMSC28 1.11 (0.91–1.35) 20 nmol/L 0.38 – – – –
SCC – – – 1.02 (0.88–1.19) 20 nmol/L 0.77 Multiply by 1
BCC – – – 1.18 (1.05–1.33) 20 nmol/L 0.01 Multiply by 1
Neuroblastoma53 0.77 (0.22–2.70) 25 nmol/L 0.69 0.74 (0.42–1.29) 25 nmol/L 0.29 Multiply by 1.25
Epithelial ovarian cancer10 1.02 (0.72–1.44) Per unit log
(25OHD)
0.93 0.78 (0.63–0.96) Per unit log
(25OHD)
0.03 Use log(OH)D betas
Clear cell 1.75 (0.77–3.99) Per unit log
(25OHD)
0.18 0.67 (0.34–1.34) Per unit log
(25OHD)
0.36 Use log(OH)D betas
Endometrioid 0.83 (0.46–1.50) Per unit log
(25OHD)
0.54 0.87 (0.54–1.41) Per unit log
(25OHD)
0.56 Use log(OH)D betas
High-grade serous 0.98 (0.61–1.56) Per unit log
(25OHD)
0.92 0.82 (0.63–1.07) Per unit log
(25OHD)
0.15 Use log(OH)D betas
Low-grade serous 0.64 (0.24–1.75) Per unit log
(25OHD)
0.39 0.95 (0.44–2.08) Per unit log
(25OHD)
0.99 Use log(OH)D betas
Mucinous 1.27 (0.56–2.87) Per unit log
(25OHD)
0.57 0.86 (0.50–1.50) Per unit log
(25OHD)
0.58 Use log(OH)D betas
Pancreatic cancer53 1.31 (0.75–2.33) 25 nmol/L 0.35 0.93 (0.46–1.92) 25 nmol/L 0.99 Multiply by 1.25
Prostate cancer29 1.00 (0.93–1.07) 25 nmol/L 0.99 1.07 (0.89–1.29) 25 nmol/L 0.46 Multiply by 1.25
ER refers to oestrogen receptor status. EC and NEEC endometrial cancer refer to the endometrioid and non-endometrioid endometrial cancer subtypes. The linear conversion factor is a scaling parameter
to align estimates to the same scale used in previously reported estimates. Here we assume a one SD change in 25(OH)D is approximately equivalent to a 20-nmol/L change based on the distribution of
25(OH)D in the UK Biobank cohort. For ovarian cancer histotypes, we used the beta estimate obtained from the log(25(OH)D GWAS (instead of rank-transformed 25(OH)D) to draw a direct
comparison with previous findings reported for per unit increase in log(25(OH)D). All P-values derived from z-scores are two-sided and unadjusted for multiple comparison unless otherwise stated.
BE Barrett’s oesophagus, EA oesophageal adenocarcinoma, SCC squamous cell carcinoma, BCC basal cell carcinoma, LAC lung adenomacarcinoma, SCLC squamous cell lung cancer, NMSC non-melanoma
skin cancer.
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early 25(OH)D studies which used 2–6 SNP instruments, because
we have used 74 SNPs we were able to make good use of MR
sensitivity methods which rely on large numbers of SNPs (typically
> 10, or ideally more) to check whether the MR assumptions made
are reasonable (MR-Egger, median and mode based methods, MR-
PRESSO).
While replication MR analyses using more 25(OH)D variants
would generally strengthen genetic evidence for causality or a lack
thereof, our study has several limitations. Firstly, any observed
difference in the MR cancer estimates can be driven by differences
in the 25(OH)D effect size estimates (e.g. SUNLIGHT vs UKB). We
attempted to control any artefactual differences arising from scaling
by expressing 25(OH)D in units of SD (rank-transformed), though
it is not trivial whether these rank-based SNP-25(OH)D estimates
were more informative in characterising the MR effect sizes com-
pared to log-scaled 25(OH)D. For instance, the SUNLIGHT con-
sortium14 included participants from various European sub-
ethnicities, while the UKB vitamin D GWAS in the present analyses
were mainly conducted on the white British population. It remains
unclear which SNP-25(OH)D estimates were more robust against
population differences, although we showed that our inferences are
broadly unaffected by the choice of SNP-25(OH)D estimate. Even
with >60 SNP instruments the power to detect modest causal effects
remains limited for some cancers, as these SNPs only explain 4.0%
of variation in 25(OH)D. Residual pleiotropy and bias due to
invalid instruments remains a concern for large multi-instrument
MR studies, although we now have the luxury of efficiently utilising
several sensitivity MR techniques to ensure that our inferences
remain robust against these biases. Adopting sex-specific instru-
ment are conceptually more informative for sex-specific cancers
(such as endometrial, prostate and ovarian), but these are unlikely
to yield different findings as the genetic architecture for vitamin D
in both sexes was very similar (rg= 0.95, se= 0.02).
In our BCC and SCC GWASs, one of the cohorts in the GWAS
meta-analysis (QSkin) used “super-controls” which were screened
to have had no prior history of treatments for KC or other actinic
lesions38. The estimated OR might be inflated as the stringent
screening protocols are more likely to selectively pick up individuals
that are genetically much less likely to develop KCs compared to
using non-KC individuals as controls in the average population
(Supplementary Fig. 8). It remains unclear whether this selection
bias inflates the GWAS effect sizes on KC, translating to higher ORs
in MR studies. Finally, the multivariable MR adjustment might not
have been very effective as some of the genetic effect on sun-
exposure phenotypes relied on the accuracy of self-reported
information.
While the purpose of this study was to appraise and re-evaluate
previous findings with more data, there are some important points
to note when comparing MR-derived findings with those from
intervention studies. Linearity of effect sizes remains a strong
assumption for most MR models39, where the relationship between
25(OH)D and cancer risk is assumed to be linear across the entire
trait distribution. It is possible to fit MR models including non-
linear terms40 to assess whether people with very low levels of 25
(OH)D are at altered risk, although in such cases our power to
detect non-linear associations would be low. RCTs remain the gold
standard to establish evidence for causality, although MR can help
examine observational hypotheses by limiting bias due to envir-
onmental confounding and cases where RCTs are less powered to
detect effects on rarer cancers. Finally, estimates derived from MR
reflect a life-long (genetic) predisposition on the exposure (vitamin
D levels) which is different from the relatively short term temporal
change in exposure induced by supplements in clinical trials41.
Even though the multi-instrument approach based on >60 SNPs
was more informative than the six SNPs used in recent studies, the
heterogeneity of the estimates among the 25(OH)D variants for
some cancers (i.e. melanoma, lung, prostate, pancreatic, neuro-
blastoma) was slightly higher and hence resulted in wider
confidence intervals. To address this concern especially for skin
cancers, we recomputed the MR association using instruments
defined at p-value < 5e-8 and that were not associated with skin-
related traits to inspect whether the increased heterogeneity on
MR estimates is due to pleiotropic effects. The difference in estimates
from the filtered set of instruments was negligible and unlikely to
meaningfully change our findings. Moreover, estimates from MR-
PRESSO, which is designed to discard outlier instruments with
strong heterogeneity on the causal estimates for each cancer type
investigated, were very similar to those evaluated using the original
IVW model.
In conclusion, our revised MR estimates using more variants
associated with 25(OH)D reinforce the existing body of genetic
evidence suggesting that 25(OH)D concentration is not associated
with risk of breast, prostate, melanoma, oesophageal and lung
cancer, with tighter confidence intervals around the null. This is
also the first vitamin D MR finding for endometrial cancer, and
shows no evidence for a causal relationship between the two. Using
a large set of genetic instruments, we were able to clarify that there
does appear to be an association between higher genetically pre-
dicted 25(OH)D levels and reduced risk of ovarian cancer. These
findings were consistent under alternative MR models robust
against bias due to pleiotropy. We detected an initial association
between 25(OH)D and basal cell carcinoma, although this was
attenuated in our multivariable framework adjusting for pigmen-
tation and sun exposure. These findings do not support the wide-
spread use of vitamin D supplementation for prevention for most
cancers, although a potential beneficial effect cannot be ruled out,
Table 4 Multivariable MR model on skin-related cancers adjusting for episodes of childhood sunburn and pigmentation.
Risk factors in multivariate
MR model
Outcome Marginal BETA SE P-value OR (95% CI) per unit change in
risk factor
Episodes of childhood sunburn Melanoma 0.33 0.26 0.21 1.39 (0.83–2.34)
Skin colour Melanoma 0.06 0.25 0.81 1.06 (0.65–1.72)
25(OH)D concentration (SD unit) Melanoma 0.15 0.11 0.18 1.16 (0.94–1.43)
Episodes of childhood sunburn BCC 2.16 0.18 5.62E-34 8.63 (6.09–12.21)
Skin colour BCC −0.44 0.16 7.09E-03 0.65 (0.47–0.89)
25(OH)D concentration (SD unit) BCC 0.14 0.07 0.07 1.15 (0.99–1.32)
Episodes of childhood sunburn SCC 2.87 0.23 4.62E-35 17.68 (11.21–27.88)
Skin colour SCC −0.16 0.22 0.44 0.85 (0.56–1.29)
25(OH)D concentration (SD unit) SCC 0.08 0.10 0.44 1.08 (0.89–1.31)
Marginal BETA reflects the marginal magnitude of association between the genetic effect of 25(OH)D SNPs exert on the risk factor of interest and skin cancer outcomes after conditioning on the genetic
effect on remaining risk factors. All P-values are derived from z-scores of the MR association (two-sided) and unadjusted for multiple comparison unless otherwise stated.
BCC basal cell carcinoma, SCC squamous cell carcinoma.
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especially for rarer cancers. The protective association between 25
(OH)D and ovarian cancer should be explored in further studies to
determine if supplementation would provide practical benefits for
this particular cancer.
Methods
Identifying genetic instruments for serum 25(OH)D using the UK Biobank
cohort. The UK Biobank cohort (UKB) comprises close to half a million participants
aged between 37 and 70 years from across the United Kingdom. Individual-level data
for serum 25(OH)D concentration were obtained from the recent UK Biobank
(March 2019) biochemistry data release. Preparation and cleaning of the genotype
data has been previously described42. Of the 438,870 white British (WB) individuals
identified based on genetic principal component clustering analyses43, 401,529 had
serum 25(OH)D data. We performed a genome-wide association study on serum 25
(OH)D concentration to identify genetic instruments for the MR analyses of cancer
risk. Serum 25(OH)D concentration was first rank-transformed (inverse normal
transformation) to allow SNP-25(OH)D effect sizes to be interpreted on a standar-
dised Z-score scale. The GWAS was run using a linear mixed model framework
accounting for relatedness, implemented using BOLT-LMM v2.244. We adjusted for
participant age, sex, top 10 ancestral principal components and the month of serum
extraction to account for seasonal variation in sun exposure. The following criteria
were used to identify genetic instruments for 25(OH)D: SNP-25(OH)D association
p-value < 5e-8 (to avoid weak instrument bias) and minor allele frequency (MAF) >
0.01. Instruments were then clumped using a window of 10Mb and maximal linkage
disequilibrium of r2= 0.001 between instruments to ensure that SNPs were inde-
pendent. The proportion of phenotypic variance in 25(OH)D explained by SNPs was
calculated to assess statistical power for the MR analyses (Supplementary methods).
The functional annotation for each of the genome-wide significant SNPs after LD-
clumping was done via the --annotate command in PLINK v1.9b45 to obtain the list
of nearby genes for each variant (Supplementary Data 4).
Obtaining instruments for skin exposure traits. For the multivariable MR ana-
lysis on skin-related cancers (details of the analysis expanded below), we also esti-
mated the joint effect of 25(OH)D instruments along with episodes of childhood
sunburn and skin colour on risk of skin cancers. These phenotypes, obtained through
questionnaires, were available in the UK Biobank. In brief, we obtained self-reported
data on: episodes of childhood sunburn from 331,020 and skin colour from 433,288
WB UKB participants with suitable genetic data. The complete list of the sun
exposure traits considered for the multivariable MR analysis together with the phe-
notype definitions and preparation for GWAS on these traits are described in greater
detail in Supplementary methods.
Description of individual cancer outcomes. Genetic summary data for each cancer
were obtained from several large cancer consortia where possible, and/or from
additional population-based cohort and case-control studies. Data for melanoma,
endometrial, ovarian and oesophageal cancers were obtained through approved data
requests to use the GWAS summary statistics granted by the respective consortia (see
below). Genetic summary data for cancers that were obtained from publicly available
repositories are listed in Supplementary material. The breakdown of each cancer
outcome evaluated is provided in Table 1. Brief descriptions of the GWASs obtained
for each cancer are provided below.
Breast cancer. Genetic summary data for breast cancer was obtained from
Michailidou and colleagues46, and can be obtained from the Breast Cancer Asso-
ciation Consortium (BCAC) online repository. The breast cancer GWAS meta-
analysis was based on 122,977 cases and 105,974 healthy controls obtained from a
combination of case-control studies and large population-based cohorts that took part
in BCAC and several other large GWAS consortia. Genetic QC procedures are
described elsewhere46.
Epithelial ovarian cancer. The GWAS summary data for EOC was retrieved from the
Phelan and colleagues47 study performed using data from the Ovarian Cancer
Association Consortium (OCAC). In total, the study included 25,509 women diag-
nosed with EOC and 40,941 control women. For the most common subtype, high-
grade serous ovarian cancer (HGSOC), the GWAS was derived from 13,037 cases and
40,941 controls; the distributions of cases for remaining subtypes are shown in
Table 1.
Endometrial cancer. We used the endometrial cancer GWAS summary statistics
reported in O’Mara and colleagues48 which were derived from 12,906 cases and
108,979 controls across various European studies that are part of the international
Endometrial Cancer Association Consortium (ECAC). Specific details on the geno-
typing and QC procedure were presented in the original GWAS article.
Prostate cancer. The GWAS summary statistics for prostate cancer were obtained
from Schumacher and colleagues49 based on data from the PRACTICAL consortium.
The prostate cancer GWAS included 79,148 cases and 61,106 controls from partici-
pants of European ancestry who were recruited for studies from around the world.
Melanoma and keratinocyte cancers. The melanoma GWAS dataset was obtained
from the 2015 melanoma GWAS meta-analyses50 comprising 12,874 cases and 23,203
controls from populations of European ancestry. For keratinocyte cancers (KC), we
performed separate fixed effect inverse-variance-weighted squamous cell carcinoma
(SCC) and basal cell carcinoma (BCC) meta-analysis of GWAS summary data
available in Liyanage and colleagues51, derived from 23andMe, Inc., a personal
genetics company, and the QSkin38 cohort. The UKB samples were excluded to
ensure non-overlapping samples in the two-sample MR framework (see below).
QSkin data were collected from participants of European ancestry currently residing
in Queensland, Australia and consist of 1995 BCC cases, 821 SCC cases and 4797
controls38. Detailed information about genotyping and quality control of QSkin BCC
and SCC GWASs and cleaning of the 23andMe data were provided previously51, and
the cohort description is outlined in supplementary methods.
Oesophageal cancer. Barret’s oesophagus (BE) is a precursor condition that is
strongly associated with oesophageal adenocarcinoma (EA). Given the strong genetic
correlation between the two diseases52, we decided to combine both of these diseases
into a single outcome (BEEA) to maximise the number of cases. For BEEA
(including BE and EA separately), the GWAS findings were previously reported in
Gharahkhani and colleagues52; the GWASs were conducted using 6167 BE patients,
4112 EA patients and 17,159 controls, all of whom were of European ancestry and
were recruited from 15 epidemiologic studies from Australia, Europe and North
America as part of the Barrett’s and Oesophageal Adenocarcinoma Consortium
(BEACON); and studies from Born, Germany; Oxford and Cambridge in the United
Kingdom. Specific details on the study participants, genotyping and imputation were
previously reported52. GWAS summary statistics for the risk of BEEA combined
were used for the main analysis; we retained the summary statistics for BE and EA
separately for sensitivity analyses.
Datasets from MR-base for lung cancer, pancreatic cancer and neuroblastoma. we
did not have access to GWAS summary statistics generated from large consortia for
other cancers including lung, pancreatic and neuroblastoma53. We relied on the
curated dataset available from the MR-Base online platform54 to perform a two-
sample MR analyses using the UKB 25(OH)D instruments. The corresponding study
reference for each of the cancer datasets and their respective sample sizes are listed in
Table 1. We applied a similar approach to evaluate the MR association under multiple
MR estimators as previously discussed.
Two-sample MR analysis. The two-sample MR framework is a powerful sta-
tistical approach that allows for causal inference analyses in the absence of
individual-level data, as it only requires genetic estimates obtained via GWAS
summary statistics. To ensure that these inferences are not biased by reverse
causality, the samples used to derive SNP-25(OH)D and SNP-cancer associa-
tions have to be independent by design55. LD-proxies for 25(OH)D SNPs were
applied (LD r2 with tagged 25(OH)D SNP > 0.8) where the SNPs of interest were
not well-imputed/genotyped from cancer GWAS summary statistics. Prior to
any MR analyses, we first performed a standard allele harmonisation to align
alleles on the forward strand. Here palindromic SNPs with a non-inferrable
allele frequency (MAF > 0.3) were excluded from the analysis. For each cancer
trait evaluated, we first estimated the MR association between 25(OH)D and
cancer using the inverse-variance weighted (IVW) estimator which combines the
SNP-25(OH)D and SNP-cancer association across multiple 25(OH)D instru-
ments. The weighted median, weighted mode and MR-Egger estimators were
then applied to help triangulate causal inference in the presence of a small
proportion of invalid instruments or directional pleiotropy bias56–58. The MR-
PRESSO22 technique was also applied to provide an MR estimate which is robust
against the presence of heterogeneity among SNP effects. The estimated MR
association between 25(OH)D and cancer risk was expressed in odds ratio (OR)
of cancer per one standard deviation (SD) increase in genetically predicted 25
(OH)D concentration. Multivariable MR adjusting for the effect of pigmentation
and sun exposure on skin cancers
Darker pigmentation reduces the amount of vitamin D obtained through sun
exposure59. Moreover, a recent study in Australian twins showed evidence of a
shared genetic architecture between pigmentation traits and 25(OH)D
concentration60. Interpreting genetic findings can hence become difficult as
variants influencing serum 25(OH)D might act through changes in pigmentation/
skin colour or sun exposure, which are themselves independent risk factors for skin
cancers61. This can potentially violate the exclusion restriction MR assumption. To
estimate a direct effect between genetic 25(OH)D and skin cancers not influenced
by these risk factors, we first fitted multivariable MR models conditioning on
factors related to proxies of outdoor activity, skin colour, hair colour, episodes of
childhood sunburn, and skin aging. This is particularly important to remove
potential bias due to horizontal pleiotropy. SNPs achieving genome-wide
significance for each trait were included in the multivariable MR analysis (see
Supplementary methods). We first evaluated the strength of the instrument in a
multivariable MR setting using the conditional F-statistics (cond. F-stat); we
dropped traits that did not fulfil criteria of strong instrument (i.e. cond. F-stat > 10)
from the multivariable MR analysis, and to reduce collinearity only picked one trait
for each category (from pigmentation-related, chronic sun exposure and time spent
outdoors traits). In our final multivariable MR model we included skin colour
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(cond. F-stat 11.4), episodes of childhood sunburn (cond. F-stat 13.1) and 25(OH)
D (cond. F-stat 59.4) (Supplementary Table 9). The multivariable MR analysis was
performed by jointly fitting the SNP-25(OH)D and SNP-skin trait effect sizes
simultaneously in the weighted regression model on the SNP-cancer association.
These analyses were conducted using the mv_multiple() function available in the
TwoSampleMR package in R curated in the MR-Base platform54.
Reverse MR analysis. We also evaluated whether there is genetic evidence for a
reverse causal effect where disease (cancer) status consequently altered serum 25
(OH)D levels by performing a bi-directional MR analysis. Here, genome-wide
loci for each cancer were selected and clumped as independent instruments for
cancer exposure. The curation of cancer exposure instruments are elaborated in
the supplementary methods. Effect estimates on 25(OH)D are expressed for a
doubling of odds of cancer (i.e. multiplying the MR estimate by ln(2)~=0.693).
The purpose of the reverse MR analyses is to assess evidence of reverse causality
- a situation where higher genetic liability to cancers might have an effect on 25
(OH)D levels.
Sensitivity analyses. A series of MR sensitivity analyses were performed to
ensure that our findings were robust against weak violation of MR assumptions.
First, we evaluated whether the genetic archictecture for 25(OH)D differed by
sex by assessing the genetic correlation between 25(OH)D in both sexes via
bivariate LD-score regression62. For cancers where the incidence greatly differs
by sex, we repeated our analyses using 25(OH)D instruments and SNP-25(OH)D
effect estimates calibrated in males and females separately. Cochran Q tests were
used to evaluate the presence of global heterogeneity in MR estimates for each
cancer. We also evaluated the impact of adjusting for vitamin D supplementa-
tion use by comparing our MR findings with those derived using the Revez et al.
SNP instruments.
Complementing our multivariable MR analyses on skin cancers, we repeated our
MR analyses using only a filtered set of variants that are not associated with skin-
related traits to reduce the potential bias in MR findings for these cancers due to
horizontal pleiotropy. This was done by removal of 25(OH)D SNPs that are
associated (p < 1e-5) with pigmentation, skin aging or tanning in both the UK
Biobank and QSkin cohort. MR scatter plots and funnel plots were also generated
for each cancer trait evaluated to allow physical inspection of potential SNP outliers.
Literature review of MR studies on 25(OH)D and cancers. We performed a
literature search in the PUBMED database for previously published MR findings
on 25(OH)D and susceptibility to any of the cancers included. Full details on the
search strategy and the search terms applied are provided in supplementary
methods. For each of these cancers, we prioritise reporting the largest study to date
as defined by the analysis with the largest number of cancer cases evaluated with
the greatest amount of 25(OH)D variance explained by SNP instruments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Summary data from each consortium is obtained from their respective public data
repositories. The data from BCAC can be accessed here [http://bcac.ccge.medschl.cam.ac.
uk/bcacdata/oncoarray/]. The GWAS summary statistics for the prostate cancer risk is
available here [http://practical.icr.ac.uk/blog/?page_id=8164]. The ovarian cancer GWAS
data can be obtained through written request to the OCAC program committee
[http://ocac.ccge.medschl.cam.ac.uk/]. The ILCCO GWAS for lung cancer as well as the
genetic summary data on neuroblastoma and pancreatic cancer (PanScan) were already
deposited in the MR-Base database [http://app.mrbase.org/]. Genetic summary data for
melanoma (GenoMEL) and oesophageal cancers (ECC) were provided through formal
application for use of the data through the respective program committee for each
consortium. Data for the SCC and BCC GWAS meta-analysis can be obtained via written
request to Dr. Stuart MacGregor (email: stuart.macgregor@qimrberghofer.edu.au),
excluding the 23andMe data. The individual-level phenotype and genotype data for UK
Biobank can be accessed through formal application to the UK Biobank via [https://www.
ukbiobank.ac.uk/]. The GWAS summary statistics for keratinocyte cancers from the
23andMe dataset will be made available through 23andMe to qualified researchers under
an agreement with 23andMe that protects the privacy of the 23andMe participants.
Please visit [https://research.23andMe.com/collaborate] for more information and to
apply to access the data. The authors declare that all other data supporting the findings of
this study are available within the paper and its supplementary information files.
Code availability
The GWAS analysis for 25(OH)D was performed using BOLT-LMM v2.3.4 (available in
http://data.broadinstitute.org/alkesgroup/BOLT-LMM/). Association analysis performed
in open-source statistical software R v4.0.2 [https://www.r-project.org/] using the
TwoSample Mendelian randomization R package [https://github.com/MRCIEU/
TwoSampleMR]. Illustrations produced using the ggplot2 v3.2.1R package available from
the R CRAN repository (https://cran.r-project.org/).
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